Results 221 to 230 of about 41,600 (260)

Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor? [PDF]

Case Rep Gastroenterol
Bayoumy AB, Masclee GMC, de Boer NKH, Neefjes-Borst A, Stenvers DJ.   +4 more
europepmc   +1 more source

Dipeptidyl peptidase 4 as an injury-responsive protein in the mouse sciatic nerve. [PDF]

Mol Cells
Oh Y, Cho Y.
europepmc   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study. [PDF]

Ophthalmol Sci
Lu YA, Tien PT, Cheng YD, Hsieh YW, Cho DY, Tsai SF, Weng CH, Lin HJ, Lin HJ, Wang IJ, Chou CC.   +10 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review

Clinical Therapeutics, 2011
Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Julienne Kirk
exaly   +3 more sources

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

Drugs, 2011
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire   +2 more sources

Highlight: Dipeptidyl peptidase 4 and related proteins

Biological Chemistry, 2011
No abstract ...
Torsten, Hoffmann, Hans-Ulrich, Demuth
openaire   +2 more sources